Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02919475
Other study ID # AE051-G-13-003
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 14, 2016
Est. completion date June 25, 2018

Study information

Verified date June 2021
Source Akros Pharma Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of JTE-051 administered for 12 weeks in subjects with active rheumatoid arthritis who are receiving background non-biologic disease-modifying anti-rheumatic drug therapy.


Recruitment information / eligibility

Status Completed
Enrollment 260
Est. completion date June 25, 2018
Est. primary completion date June 25, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - A diagnosis of RA prior to the Screening Visit. - Active disease despite ongoing therapy with up to two non-biologic disease-modifying anti-rheumatic drugs, including methotrexate at both the Screening and Baseline Visits. - Screening hs-CRP =1.2 x upper limit of normal (ULN). Exclusion Criteria: - Prior/current exposure to biologic and/or kinase inhibitor therapy. - Known history or presence of polyneuropathy of any cause and no presence of clinically active compression neuropathy, radiculopathy or plexopathy at the Screening Visit. - Positive test results for human immunodeficiency (HIV) virus, hepatitis B virus or hepatitis C (HCV) virus at the Screening Visit. - Positive drug of abuse and alcohol test results. - History of a clinically-significant infection that required oral antimicrobial or antiviral therapy within 8 weeks prior to Day 1.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
JTE-051
Active drug tablets containing JTE-051
Placebo
Placebo tablets identical in appearance to the active drug tablets

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Akros Pharma Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Bulgaria,  Colombia,  Mexico,  Peru,  Poland,  Romania,  Russian Federation,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Subjects Achieving at Least 20% Improvement From Baseline in American College of Rheumatology (ACR) Core Set Measures (ACR20 Response Rate) Compared to Placebo at End-of-treatment (EOT) Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at EOT (up to Week 12) compared to placebo.
The ACR core set measures are:
Tender joint count
Swollen joint count
Subject Assessment of arthritis pain
Subject's Global Assessment of disease activity (SGA)
Physician's Global Assessment of disease activity (PGA)
Health Assessment Questionnaire Disability Index (HAQ-DI)
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)
Up to 12 Weeks
Secondary Percentage of Subjects Achieving ACR20 Response Rate Compared to Placebo at Week 12 Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo.
The ACR core set measures are:
Tender joint count
Swollen joint count
Subject Assessment of arthritis pain
Subject's Global Assessment of disease activity (SGA)
Physician's Global Assessment of disease activity (PGA)
Health Assessment Questionnaire Disability Index (HAQ-DI)
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)
Week 12
Secondary Percentage of Subjects Achieving ACR50 Response Rate Compared to Placebo at Week 12 Percentage of subjects achieving at least 50% improvement from baseline (ACR50) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 50% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo.
The ACR core set measures are:
Tender joint count
Swollen joint count
Subject Assessment of arthritis pain
Subject's Global Assessment of disease activity (SGA)
Physician's Global Assessment of disease activity (PGA)
Health Assessment Questionnaire Disability Index (HAQ-DI)
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)
Week 12
Secondary Percentage of Subjects Achieving ACR70 Response Rate Compared to Placebo at Week 12 Percentage of subjects achieving at least 70% improvement from baseline (ACR70) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 70% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo.
The ACR core set measures are:
Tender joint count
Swollen joint count
Subject Assessment of arthritis pain
Subject's Global Assessment of disease activity (SGA)
Physician's Global Assessment of disease activity (PGA)
Health Assessment Questionnaire Disability Index (HAQ-DI)
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)
Week 12
Secondary Change From Baseline in SDAI (Simplified Disease Activity Index) at Week 12 The SDAI Scores indicate how active a patient's rheumatoid arthritis (RA) is currently. The SDAI is the sum of 5 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10), Physician's Global Score of disease activity (0 to 10) and C-reactive protein (CRP, 0 to 10).General SDAI Score Interpretation is as follows:
0.0 - 3.3 Remission 3.4 - 11.0 Low Activity 11.1 - 26.0 Moderate Activity 26.1 - 86.0 High Activity
Week 12
Secondary Change From Baseline in CDAI (Clinical Disease Activity Index) at Week 12 The CDAI is a useful clinical composite score for following patients with rheumatoid arthritis (RA). The CDAI is the sum of 4 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10) and Physician's Global Score of disease activity (0 to 10). The CDAI Score Interpretation is as follows:
0 to 2.8: Remission 2.9 to 10: Low Disease Activity 10.1 to 22: Moderate Disease Activity 22.1 to 76: High Disease Activity
Week 12
Secondary Change From Baseline in DAS28-CRP (Disease Activity Score [DAS] Based on High-sensitivity C-reactive Protein [Hs-CRP]) at Week 12 Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consists of composite score of following variables: 28 tender joint count (TJC28) ranging from 0 to 28, 28 swollen joint count (SJC28) ranged from 0 to 28, C-reactive protein (CRP) (milligrams per liter) and subject's global assessment of disease activity (SGA) ranging from 0 (no disease activity) to 10 (extremely active disease). DAS28-CRP was calculated using following formula:
DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*SGA+0.96.
DAS28-CRP ranged from 0.96-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP <2.6.
A decrease in DAS28-CRP indicated an improvement in participant's condition.
Week 12
Secondary Change From Baseline in HAQ-DI (Health Assessment Questionnaire Disability Index) at Week 12 The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] in 8 functional area categories: (1) dressing and grooming; (2) arising; (3) eating; (4) walking; (5) hygiene; (6) reaching; (7) gripping; and (8) performing other daily activities. Scores from each functional area category (total 8 categories) were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. Week 12
Secondary Number of Subjects With Treatment-related Adverse Events Subjects in the Safety Population (258, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The number of subjects in the Safety Population is 258 subjects, which is 1 less than the Randomized Population of 259 subjects, since 1 randomized subject did not receive any study drug. Up to 16 Weeks
Secondary Trough Concentrations (Ctrough) of JTE-051 in Plasma at Week 12 Week 12
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4